Shannon Thyme Klinger, Moderna's Chief Legal Officer, has executed a significant transaction involving the company's equity. On June 4, 2026, Klinger sold 3,471 shares of Moderna common stock, generating gross proceeds totaling $173,550. The shares were divested at a price of $50.00 per share. This sale was conducted under a Rule 10b5-1 trading plan that was originally adopted on September 9, 2025.
The timing of this transaction is notable given Moderna's recent market performance. The company's stock has delivered a 73% return over the past year. At the time of the sale, Moderna shares were trading at $47.60, supporting a market capitalization of $18.9 billion. Following the reported transactions, Ms. Klinger's direct holdings in Moderna common stock stand at 73,561 shares.
The June 4 transaction was part of a broader sequence of equity movements. Earlier that same day, Ms. Klinger acquired 3,471 shares of common stock through the exercise of stock options. These options were exercised at a price of $30.96 per share. The options became exercisable starting March 1, 2026, with the remainder vesting in quarterly installments thereafter. This acquisition was also conducted under the established Rule 10b5-1 trading plan.
On June 5, 2026, the equity activity continued with the vesting of restricted stock units. Ms. Klinger acquired an additional 11,798 shares due to the vesting of restricted stock units. These units convert into common stock on a one-for-one basis. The restricted stock units began vesting on December 5, 2025, with subsequent quarterly installments. In total, these acquisitions amounted to $107,462, with prices ranging from $0.00 to $30.96 per share.
Associated with these vesting events, tax withholding obligations were satisfied on June 5, 2026. A total of 5,705 shares of common stock, valued at $294,320, were withheld for this purpose. The shares were valued at $51.59 per share for the calculation of these tax obligations.
Moderna's corporate governance and pipeline activities are also evolving. The company announced plans to develop an mRNA-based hantavirus vaccine. This initiative involves a research agreement with Korea University as part of Moderna's mRNA Access Program. The announcement follows reports of hantavirus cases on a cruise ship, with the World Health Organization noting 11 cases, including three fatalities. Despite these reports, the WHO does not anticipate a wider outbreak.
In governance matters, Moderna amended its bylaws to designate U.S. federal district courts as the exclusive forum for certain securities-related complaints. This change aligns with recent developments in Delaware's corporate law. The company also held its 2026 Annual Meeting of Stockholders, where all agenda items were successfully voted on.
Analyst sentiment remains measured. UBS reiterated a Neutral rating for Moderna, maintaining a price target of $45.00. UBS highlighted the company's Phase III INT adjuvant melanoma interim analysis as a significant event expected in 2026. According to valuation analysis, Moderna currently appears overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list.